AR018013A1 - Una proteina de alto peso molecular (hmw) aislada de especies de chlamydia y los acidos nucleicos, vectores de expresion recombinante, celulas huespedtransformadas, proteinas recombinantes, composiciones inmunogenicas y antigenicas, metodos para producir una respuesta inmune en animales, antisueros, - Google Patents
Una proteina de alto peso molecular (hmw) aislada de especies de chlamydia y los acidos nucleicos, vectores de expresion recombinante, celulas huespedtransformadas, proteinas recombinantes, composiciones inmunogenicas y antigenicas, metodos para producir una respuesta inmune en animales, antisueros,Info
- Publication number
- AR018013A1 AR018013A1 ARP980104960A ARP980104960A AR018013A1 AR 018013 A1 AR018013 A1 AR 018013A1 AR P980104960 A ARP980104960 A AR P980104960A AR P980104960 A ARP980104960 A AR P980104960A AR 018013 A1 AR018013 A1 AR 018013A1
- Authority
- AR
- Argentina
- Prior art keywords
- chlamydia
- species
- promotional
- nucleic acids
- methods
- Prior art date
Links
- 241000606161 Chlamydia Species 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 241000894007 species Species 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 title abstract 2
- 238000003259 recombinant expression Methods 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title 2
- 102000004169 proteins and genes Human genes 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 238000001514 detection method Methods 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 3
- 241001647372 Chlamydia pneumoniae Species 0.000 abstract 2
- 241000606153 Chlamydia trachomatis Species 0.000 abstract 2
- 206010035664 Pneumonia Diseases 0.000 abstract 2
- 229940038705 chlamydia trachomatis Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 201000004569 Blindness Diseases 0.000 abstract 1
- 241001674218 Chlamydia pecorum Species 0.000 abstract 1
- 241001647378 Chlamydia psittaci Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010035742 Pneumonitis Diseases 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 208000019802 Sexually transmitted disease Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000000795 conjunctiva Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 244000052637 human pathogen Species 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 206010030861 ophthalmia neonatorum Diseases 0.000 abstract 1
- 210000005000 reproductive tract Anatomy 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56927—Chlamydia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
- Y10S530/814—Cellulose or derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se revela una proteína HMW de especies de Chlamydia y los ácidos nucleicos, vectores de expresion recombinante, células huésped transformadas, proteínasrecombinantes, composiciones inmunogénicas y antigénicas, métodos para producir una respuesta inmune en animales, antisueros, anticuerpos reactivos y equiposde diagnostico, método de deteccion y diagnostico de anticuerpos, método de deteccion y diagnostico de Chlamydia, composiciones farmacéuticas y de vacuna,métodos terapéuticos y de afeccionesrelacionadas con Chlamydia y métodos de deteccion y de diagnostico de ácidos nucleicos asociados. Las Chlamydiaconstituyen patogenos humanos de frecuente ocurrencia, que causan trastornos, tales como enfermedades transmitidas sexualmente, enfermedades respiratorias,que incluyen la neumonía, la conjuntivitis neonatal, y la ceguera. Las Chlamydia son bacterias intracelulares obligadas que infectan el revestimiento interiorepitelial del pulmon, la conjuntiva o tracto genital. Las especies más comunes de Chlamydia incluyen, Chlamydia trachomatis, Chlamydia psittaci, Chlamydiapecorum y Chlamydia pneumoniae.Recientemente, las especies nuevamente designadas de Chlamydia, Chlamydia pneumoniae (anteriormente Chlamydia trachomatis TWAR),han sido implicadas como la mayor causa de neumonitis humana epidémica y tal vez puedan jugar un papel en la aterosclerosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/942,596 US7459524B1 (en) | 1997-10-02 | 1997-10-02 | Chlamydia protein, sequence and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018013A1 true AR018013A1 (es) | 2001-10-31 |
Family
ID=25478327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104960A AR018013A1 (es) | 1997-10-02 | 1998-10-05 | Una proteina de alto peso molecular (hmw) aislada de especies de chlamydia y los acidos nucleicos, vectores de expresion recombinante, celulas huespedtransformadas, proteinas recombinantes, composiciones inmunogenicas y antigenicas, metodos para producir una respuesta inmune en animales, antisueros, |
| ARP080105319A AR069600A2 (es) | 1997-10-02 | 2008-12-05 | Composiciones que comprenden un polipeptido aislado, o un anticuerpo aislado o fragmento que se une al antigeno del mismo, y un vehiculo, los vectores de expresion, las celulas hospedantes, los reactivos de diagnostico, los metodos para detectar chlamydia, anticuerpos anti-chlamydia y acidos nucleic |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105319A AR069600A2 (es) | 1997-10-02 | 2008-12-05 | Composiciones que comprenden un polipeptido aislado, o un anticuerpo aislado o fragmento que se une al antigeno del mismo, y un vehiculo, los vectores de expresion, las celulas hospedantes, los reactivos de diagnostico, los metodos para detectar chlamydia, anticuerpos anti-chlamydia y acidos nucleic |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US7459524B1 (es) |
| EP (2) | EP1019028A4 (es) |
| JP (1) | JP2001518489A (es) |
| KR (1) | KR100586569B1 (es) |
| CN (2) | CN1911960B (es) |
| AR (2) | AR018013A1 (es) |
| AU (1) | AU752426B2 (es) |
| BR (1) | BR9813841A (es) |
| CA (1) | CA2305709A1 (es) |
| CO (1) | CO5050400A1 (es) |
| HU (1) | HUP0004639A3 (es) |
| NZ (1) | NZ503763A (es) |
| SA (1) | SA99191283B1 (es) |
| WO (1) | WO1999017741A1 (es) |
| ZA (1) | ZA989012B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
| US5868735A (en) | 1997-03-06 | 1999-02-09 | Scimed Life Systems, Inc. | Cryoplasty device and method |
| US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
| US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| NZ512730A (en) * | 1998-12-04 | 2003-12-19 | Univ Manitoba | A immunization procedure against chlamydia infection using an attenuated bacteria comprsing a plasmid with a major outer membrane protein (MOMP) from chlamydial |
| US20080213264A1 (en) * | 1998-12-08 | 2008-09-04 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20020061848A1 (en) * | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| AU780444B2 (en) * | 1999-05-03 | 2005-03-24 | Sanofi Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US6919187B2 (en) * | 2000-04-21 | 2005-07-19 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| CA2407114A1 (en) | 2000-04-21 | 2001-11-01 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
| US7731980B2 (en) * | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| EP2335723A1 (en) * | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
| US7807802B2 (en) | 2002-11-12 | 2010-10-05 | Abbott Lab | Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae |
| ITTO20050905A1 (it) * | 2005-12-23 | 2007-06-24 | Univ Degli Studi Torino | Leganti sintetici capaci di legare l'ocratossina e relativi usi |
| EP2484375B1 (en) | 2006-09-26 | 2018-05-23 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PL2086582T3 (pl) | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
| WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| US20100310593A1 (en) * | 2007-06-14 | 2010-12-09 | Emergent Product Development Gaithersburg Inc. | Vaccines Against Chlamydia Infection |
| US20090254588A1 (en) * | 2007-06-19 | 2009-10-08 | Zhong Li | Multi-Dimensional Data Merge |
| US8703153B2 (en) | 2008-06-16 | 2014-04-22 | Prokarium Ltd. | Salmonella vectored vaccines against Chlamydia and methods of use |
| WO2010005474A1 (en) * | 2008-06-16 | 2010-01-14 | Emergent Product Development Gaithersburg Inc. | Recombinant modified vaccinia virus ankara (mva) expressing chlamydia polypeptide antigens |
| WO2010085896A1 (en) | 2009-01-29 | 2010-08-05 | British Columbia Cancer Agency Branch | Compositions comprising chlamydia antigens |
| RU2732574C2 (ru) | 2009-06-05 | 2020-09-21 | Инфекшес Дизиз Рисерч Инститьют | Синтетические глюкопиранозиллипидные адъюванты |
| ES2651005T3 (es) | 2010-03-09 | 2018-01-23 | Biomedical Research Models, Inc. | Una nueva estrategia de vacunación mucosa para el virus del herpes simple tipo-2 |
| MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
| CN110339160A (zh) | 2012-02-07 | 2019-10-18 | 传染性疾病研究院 | 包含tlr4激动剂的改进佐剂制剂及其使用方法 |
| DK2850431T3 (en) | 2012-05-16 | 2018-07-16 | Immune Design Corp | Vaccines against HSV-2 |
| CA2897398A1 (en) | 2013-01-07 | 2014-07-10 | Biomedical Research Models, Inc. | Use of vaccines for the treatment of herpes simplex virus type 2 infections |
| EA032326B1 (ru) | 2013-04-18 | 2019-05-31 | Иммьюн Дизайн Корп. | Монотерапия gla для применения в лечении рака |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| EP3089754B1 (en) | 2013-12-31 | 2021-04-21 | Infectious Disease Research Institute | Single vial vaccine formulations |
| WO2017176076A1 (en) | 2016-04-06 | 2017-10-12 | Ewha University - Industry Collaboration Foundation | A peptide with ability to penetrate cell membrane |
| BR112018073690B1 (pt) | 2016-05-16 | 2022-05-24 | Infectious Disease Research Institute | Formulação contendo agonista de tlr e métodos de uso |
| KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
| MX393217B (es) | 2016-06-01 | 2025-03-11 | Infectious Disease Res Inst | Particulas de nanoalumbre que contienen un agente de dimensionamiento |
| EP3638207B1 (en) | 2017-06-15 | 2024-12-18 | Access to Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| AU2018330165B2 (en) | 2017-09-08 | 2025-07-17 | Access To Advanced Health Institute | Liposomal formulations comprising saponin and methods of use |
| US12318436B2 (en) | 2019-05-25 | 2025-06-03 | Access To Advanced Health Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| WO2022051022A1 (en) | 2020-09-04 | 2022-03-10 | Infectious Disease Research Institute | Co-lyophilized rna and nanostructured lipid carrier |
| WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
| US4427782A (en) * | 1981-03-03 | 1984-01-24 | Caldwell Harlan D | Isolation of principal outer membrane protein and antigen of Chlamydia trachomatis |
| US4952496A (en) | 1984-03-30 | 1990-08-28 | Associated Universities, Inc. | Cloning and expression of the gene for bacteriophage T7 RNA polymerase |
| DE3521994A1 (de) | 1985-06-20 | 1987-01-02 | Bayer Ag | N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US4935352A (en) | 1985-10-21 | 1990-06-19 | Takeda Chemical Industries, Ltd. | Expression vector for animal cell line and use thereof |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ATE121754T1 (de) | 1989-09-04 | 1995-05-15 | Wellcome Found | Vakzine gegen bordetella. |
| US5071962A (en) | 1990-05-31 | 1991-12-10 | The United State Of America As Represented By The Department Of Health And Human Services | Nucleotide, deduced amino acid sequence, isolation and purification of heat-shock chlamydial proteins |
| US5965141A (en) | 1991-02-15 | 1999-10-12 | Uab Research Foundation | Epitopic regions of pneumococcal surface protein a |
| US5725863A (en) * | 1991-09-06 | 1998-03-10 | The United States Of America As Represented By The Secretary Of Agriculture | Polypeptides useful in prevention of chlamydia infection |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
| IL107628A0 (en) | 1992-11-18 | 1994-02-27 | Calypte Inc | Immunoassays for microorganisms associated with sexually transmitted diseases |
| ATE286536T1 (de) | 1993-09-10 | 2005-01-15 | Us Gov Health & Human Serv | Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen |
| AU701247B2 (en) | 1993-11-03 | 1999-01-21 | Pfizer Inc. | Vaccine and method for treatment of chlamydial infections |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| US5871993A (en) | 1994-02-23 | 1999-02-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | DNA encoding enzyme, recombinant DNA and enzyme, transformant, and their preparations and uses |
| US5629167A (en) * | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| AU697218B2 (en) | 1995-03-28 | 1998-10-01 | Hitachi Chemical Company, Ltd. | Chlamydia pneumoniae antigens, method for production of the antigens, method and reagents for measurement of anti-chlamydia pneumoniae antibodies using the antigens |
| GB9506863D0 (en) | 1995-04-03 | 1995-05-24 | Smithkline Beecham Biolog | Vaccines |
| US5807978A (en) * | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| JPH09184843A (ja) * | 1995-12-28 | 1997-07-15 | Meiji Milk Prod Co Ltd | クラミジア・トラコマチス感染の診断方法 |
| US6464979B1 (en) | 1996-09-12 | 2002-10-15 | Aventis Pasteur Limited | Chlamydial vaccines and methods of preparation thereof |
| US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
| EP1032676A2 (en) | 1997-11-28 | 2000-09-06 | Genset | $i(CHLAMYDIA TRACHOMATIS) GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION |
| JP2002508182A (ja) | 1997-12-17 | 2002-03-19 | ジェンセット | 分泌タンパク質の伸長ｃＤＮＡ |
| US6077693A (en) * | 1998-05-14 | 2000-06-20 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding a promonocyte associated protein |
| US6565856B1 (en) | 1998-12-08 | 2003-05-20 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US20020061848A1 (en) | 2000-07-20 | 2002-05-23 | Ajay Bhatia | Compounds and methods for treatment and diagnosis of chlamydial infection |
| EP2277893A3 (en) | 1998-12-08 | 2011-03-30 | Corixa Corporation | Compounds and methods for treatment and diagnosis of chlamydial infection |
| US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
| GB0103169D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| US20100310593A1 (en) | 2007-06-14 | 2010-12-09 | Emergent Product Development Gaithersburg Inc. | Vaccines Against Chlamydia Infection |
| JP4743455B2 (ja) | 2009-05-26 | 2011-08-10 | トヨタ自動車株式会社 | 燃料電池システム |
-
1997
- 1997-10-02 US US08/942,596 patent/US7459524B1/en not_active Expired - Fee Related
-
1998
- 1998-10-01 WO PCT/US1998/020737 patent/WO1999017741A1/en not_active Ceased
- 1998-10-01 CN CN2006100887769A patent/CN1911960B/zh not_active Expired - Fee Related
- 1998-10-01 KR KR1020007003596A patent/KR100586569B1/ko not_active Expired - Fee Related
- 1998-10-01 CA CA002305709A patent/CA2305709A1/en not_active Abandoned
- 1998-10-01 HU HU0004639A patent/HUP0004639A3/hu unknown
- 1998-10-01 JP JP2000514618A patent/JP2001518489A/ja active Pending
- 1998-10-01 EP EP98949723A patent/EP1019028A4/en not_active Withdrawn
- 1998-10-01 BR BR9813841-3A patent/BR9813841A/pt active Search and Examination
- 1998-10-01 NZ NZ503763A patent/NZ503763A/xx not_active IP Right Cessation
- 1998-10-01 CN CNB988118173A patent/CN1268637C/zh not_active Expired - Fee Related
- 1998-10-01 AU AU95988/98A patent/AU752426B2/en not_active Ceased
- 1998-10-01 EP EP07015945A patent/EP1862472A3/en not_active Withdrawn
- 1998-10-02 ZA ZA989012A patent/ZA989012B/xx unknown
- 1998-10-02 CO CO98057476A patent/CO5050400A1/es unknown
- 1998-10-05 AR ARP980104960A patent/AR018013A1/es unknown
-
1999
- 1999-04-12 SA SA99191283A patent/SA99191283B1/ar unknown
-
2000
- 2000-04-03 US US09/542,520 patent/US6887843B1/en not_active Expired - Fee Related
- 2000-07-06 US US09/612,402 patent/US6642023B1/en not_active Expired - Fee Related
-
2003
- 2003-11-04 US US10/701,844 patent/US7419807B2/en not_active Expired - Fee Related
-
2004
- 2004-01-27 US US10/766,711 patent/US7534445B2/en not_active Expired - Fee Related
- 2004-09-01 US US10/931,779 patent/US7655246B2/en not_active Expired - Fee Related
-
2008
- 2008-12-05 AR ARP080105319A patent/AR069600A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1034187A1 (en) | 2001-10-19 |
| US20040137005A1 (en) | 2004-07-15 |
| AR069600A2 (es) | 2010-02-03 |
| US7655246B2 (en) | 2010-02-02 |
| CN1911960B (zh) | 2012-11-07 |
| US7459524B1 (en) | 2008-12-02 |
| WO1999017741A1 (en) | 1999-04-15 |
| SA99191283B1 (ar) | 2006-04-18 |
| US6887843B1 (en) | 2005-05-03 |
| CA2305709A1 (en) | 1999-04-15 |
| EP1862472A2 (en) | 2007-12-05 |
| HUP0004639A3 (en) | 2004-10-28 |
| EP1019028A4 (en) | 2002-11-20 |
| CN1911960A (zh) | 2007-02-14 |
| HUP0004639A2 (hu) | 2001-04-28 |
| EP1862472A3 (en) | 2008-03-19 |
| KR20010030902A (ko) | 2001-04-16 |
| NZ503763A (en) | 2003-01-31 |
| AU752426B2 (en) | 2002-09-19 |
| EP1019028A1 (en) | 2000-07-19 |
| JP2001518489A (ja) | 2001-10-16 |
| CN1283108A (zh) | 2001-02-07 |
| CN1268637C (zh) | 2006-08-09 |
| US20050048557A1 (en) | 2005-03-03 |
| US7534445B2 (en) | 2009-05-19 |
| US20040067524A1 (en) | 2004-04-08 |
| US7419807B2 (en) | 2008-09-02 |
| BR9813841A (pt) | 2000-10-03 |
| CO5050400A1 (es) | 2001-06-27 |
| KR100586569B1 (ko) | 2006-06-02 |
| US6642023B1 (en) | 2003-11-04 |
| AU9598898A (en) | 1999-04-27 |
| ZA989012B (en) | 1999-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018013A1 (es) | Una proteina de alto peso molecular (hmw) aislada de especies de chlamydia y los acidos nucleicos, vectores de expresion recombinante, celulas huespedtransformadas, proteinas recombinantes, composiciones inmunogenicas y antigenicas, metodos para producir una respuesta inmune en animales, antisueros, | |
| Uchiyama et al. | The major outer membrane protein rOmpB of spotted fever group rickettsiae functions in the rickettsial adherence to and invasion of Vero cells | |
| Morrison et al. | Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection | |
| Pore et al. | Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate | |
| ZHANG et al. | Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain | |
| Liu et al. | Comparative study of the vaccine potential of six outer membrane proteins of Edwardsiella tarda and the immune responses of flounder (Paralichthys olivaceus) after vaccination | |
| Rockey et al. | Protein antigens of Chlamydia psittaci present in infected cells but not detected in the infectious elementary body | |
| KR20050073865A (ko) | 비브리오 패혈증균 편모 구성인자 플라젤린을유효성분으로 함유하는 백신 보조제 | |
| Tifrea et al. | Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccine | |
| ES2586125T3 (es) | Polipéptidos de Staphylococcus aureus y métodos de uso | |
| Lin et al. | Protective effects of oral microencapsulated Mycoplasma hyopneumoniae vaccine prepared by co-spray drying method | |
| Rank et al. | Immunization against chlamydial genital infection in guinea pigs with UV-inactivated and viable chlamydiae administered by different routes | |
| Sabri et al. | Efficacy of an outer membrane protein of Pasteurella haemolytica A2, A7 or A9-enriched vaccine against intratracheal challenge exposure in sheep | |
| US20090215151A1 (en) | Two-Step Immunization Procedure Against Chlamydia Infection | |
| Zhou et al. | MOMP and MIP DNA-loaded bacterial ghosts reduce the severity of lung lesions in mice after Chlamydia psittaci respiratory tract infection | |
| Brogden et al. | Pasteurella haemolytica lipopolysaccharide-associated protein induces pulmonary inflammation after bronchoscopic deposition in calves and sheep | |
| Verminnen et al. | Protection of turkeys against Chlamydophila psittaci challenge by DNA and rMOMP vaccination and evaluation of the immunomodulating effect of 1α, 25-dihydroxyvitamin D3 | |
| Telford III et al. | Efficacy of human Lyme disease vaccine formulations in a mouse model | |
| Shaw et al. | Comparison of murine cervicovaginal infection by chlamydial strains: identification of extrusions shed in vivo | |
| Peng et al. | Efficacy of Pgp3 vaccination for Chlamydia urogenital tract infection depends on its native conformation | |
| Baumgärtner et al. | Spread and distribution of Coxiella burnetii in C57BL/6J (H-2b) and Balb/cJ (H-2d) mice after intraperitoneal infection | |
| di Girolamo et al. | Evaluation of cytokines as adjuvants of infectious bovine keratoconjunctivitis vaccines | |
| Pang et al. | Identification of novel immunogenic proteins of V ibrio alginolyticus by immunoproteomic methodologies | |
| Baghian et al. | Antibody response to epitopes of chlamydial major outer membrane proteins on infectious elementary bodies and of the reduced polyacrylamide gel electrophoresis-separated form | |
| Chidlow et al. | The role of oral immunisation in stimulating Escherichia coli antibody of the IgM class in porcine colostrum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |